By contrast, supportive of the protective antifibrotic effect of IL-9, Yanaba et al. [42] reported that elevated systemic levels of IL-9 in patients with SSc were associated with lower frequency and severity of pulmonary fibrosis. Here, IL9 is linked to systemic sclerosis.